Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixa...
02 Septembre 2017 - 12:34AM
Portola Pharmaceuticals (Nasdaq:PTLA) announced that it will
host a webcast and conference call to provide an update on
Bevyxxa
® (betrixaban) launch plans, the validation
of the commercial manufacturing process and drug release timing.
Conference Call DetailsThe live conference call
on Tuesday, September 5, 2017, at 4:30 p.m. Eastern Time (1:30 p.m.
PT)., can be accessed by phone by calling (844) 452-6828 from the
United States and Canada or 1 (765)-507-2588 internationally and
using the passcode 75259872. The webcast can be accessed live on
the Investor Relations section of the Company's website at
http://investors.portola.com. It will be archived for 30 days
following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company’s
first medicine Bevyxxa® (betrixaban), an oral,
once-daily Factor Xa inhibitor, was approved by the U.S. Food and
Drug Administration in June 2017. The company is also working to
advance two clinical programs for andexanet alfa, a recombinant
protein designed to reverse the anticoagulant effect in patients
treated with an oral or injectable Factor Xa inhibitor; and
cerdulatinib, a SYK/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective SYK inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and follow
the Company on Twitter @Portola_Pharma.
Investor Contact:
Michele Mantynen
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Jacquelyn Matter
Pure Communications
jmatter@purecommunications.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur